Intra-cellular Therapies

Intra-Cellular Therapies is a biopharmaceutical company focused on the development and commercialization of innovative treatments for neuropsychiatric and neurodegenerative disorders. They generate revenue primarily through the sales of their FDA-approved drug, Caplyta, which is used to treat schizophrenia and bipolar depression. Founded in 2002, the company has a strong research foundation, leveraging its proprietary ITI platform to discover novel drug candidates. Their commitment to addressing unmet medical needs in mental health is a key aspect of their mission and operations.

Recent Posts by Intra-cellular Therapies

1-20 of 34